Abstract
Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand the mechanisms that lead to treatment resistance. To this end, we analyzed whole-exome sequencing data of eight chronic lymphocytic leukemia (CLL) patients that developed resistance upon BCL2-inhibition by venetoclax. Here, we report recurrent mutations in BTG1 (2 patients) and homozygous deletions affecting CDKN2A/B (3 patients) that developed during treatment, as well as a mutation in BRAF and a high-level focal amplification of CD274 (PD-L1) that might pinpoint molecular aberrations offering structures for further therapeutic interventions.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
-
Cyclin-Dependent Kinase Inhibitor p15 / genetics
-
Cyclin-Dependent Kinase Inhibitor p15 / metabolism
-
Cyclin-Dependent Kinase Inhibitor p16
-
Cyclin-Dependent Kinase Inhibitor p18 / genetics
-
Cyclin-Dependent Kinase Inhibitor p18 / metabolism
-
Drug Resistance, Neoplasm*
-
Female
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
-
Male
-
Mutation
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism
-
Sulfonamides / therapeutic use*
Substances
-
Bridged Bicyclo Compounds, Heterocyclic
-
CDKN2A protein, human
-
CDKN2B protein, human
-
Cyclin-Dependent Kinase Inhibitor p15
-
Cyclin-Dependent Kinase Inhibitor p16
-
Cyclin-Dependent Kinase Inhibitor p18
-
Neoplasm Proteins
-
Sulfonamides
-
BTG1 protein, human
-
venetoclax